We also evaluated the anti-tumor effects of a novel treatment strategy involving the co-administration of Fasudil and an EGFR-TKI (gefitinib) in gefitinib-resistant EGFR-mutation NSCLC using in vivo and vitro models. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.